Literature DB >> 27433846

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.

Colin C Pritchard1, Joaquin Mateo1, Michael F Walsh1, Navonil De Sarkar1, Wassim Abida1, Himisha Beltran1, Andrea Garofalo1, Roman Gulati1, Suzanne Carreira1, Rosalind Eeles1, Olivier Elemento1, Mark A Rubin1, Dan Robinson1, Robert Lonigro1, Maha Hussain1, Arul Chinnaiyan1, Jake Vinson1, Julie Filipenko1, Levi Garraway1, Mary-Ellen Taplin1, Saud AlDubayan1, G Celine Han1, Mallory Beightol1, Colm Morrissey1, Belinda Nghiem1, Heather H Cheng1, Bruce Montgomery1, Tom Walsh1, Silvia Casadei1, Michael Berger1, Liying Zhang1, Ahmet Zehir1, Joseph Vijai1, Howard I Scher1, Charles Sawyers1, Nikolaus Schultz1, Philip W Kantoff1, David Solit1, Mark Robson1, Eliezer M Van Allen1, Kenneth Offit1, Johann de Bono1, Peter S Nelson1.   

Abstract

BACKGROUND: Inherited mutations in DNA-repair genes such as BRCA2 are associated with increased risks of lethal prostate cancer. Although the prevalence of germline mutations in DNA-repair genes among men with localized prostate cancer who are unselected for family predisposition is insufficient to warrant routine testing, the frequency of such mutations in patients with metastatic prostate cancer has not been established.
METHODS: We recruited 692 men with documented metastatic prostate cancer who were unselected for family history of cancer or age at diagnosis. We isolated germline DNA and used multiplex sequencing assays to assess mutations in 20 DNA-repair genes associated with autosomal dominant cancer-predisposition syndromes.
RESULTS: A total of 84 germline DNA-repair gene mutations that were presumed to be deleterious were identified in 82 men (11.8%); mutations were found in 16 genes, including BRCA2 (37 men [5.3%]), ATM (11 [1.6%]), CHEK2 (10 [1.9% of 534 men with data]), BRCA1 (6 [0.9%]), RAD51D (3 [0.4%]), and PALB2 (3 [0.4%]). Mutation frequencies did not differ according to whether a family history of prostate cancer was present or according to age at diagnosis. Overall, the frequency of germline mutations in DNA-repair genes among men with metastatic prostate cancer significantly exceeded the prevalence of 4.6% among 499 men with localized prostate cancer (P<0.001), including men with high-risk disease, and the prevalence of 2.7% in the Exome Aggregation Consortium, which includes 53,105 persons without a known cancer diagnosis (P<0.001).
CONCLUSIONS: In our multicenter study, the incidence of germline mutations in genes mediating DNA-repair processes among men with metastatic prostate cancer was 11.8%, which was significantly higher than the incidence among men with localized prostate cancer. The frequencies of germline mutations in DNA-repair genes among men with metastatic disease did not differ significantly according to age at diagnosis or family history of prostate cancer. (Funded by Stand Up To Cancer and others.).

Entities:  

Mesh:

Year:  2016        PMID: 27433846      PMCID: PMC4986616          DOI: 10.1056/NEJMoa1603144

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  39 in total

1.  Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Authors:  Fritz H Schröder; Jonas Hugosson; Sigrid Carlsson; Teuvo Tammela; Liisa Määttänen; Anssi Auvinen; Maciej Kwiatkowski; Franz Recker; Monique J Roobol
Journal:  Eur Urol       Date:  2012-06-07       Impact factor: 20.096

2.  BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

Authors:  Kathryn Alsop; Sian Fereday; Cliff Meldrum; Anna deFazio; Catherine Emmanuel; Joshy George; Alexander Dobrovic; Michael J Birrer; Penelope M Webb; Colin Stewart; Michael Friedlander; Stephen Fox; David Bowtell; Gillian Mitchell
Journal:  J Clin Oncol       Date:  2012-06-18       Impact factor: 44.544

3.  ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing.

Authors:  Colin C Pritchard; Christina Smith; Stephen J Salipante; Ming K Lee; Anne M Thornton; Alex S Nord; Cassandra Gulden; Sonia S Kupfer; Elizabeth M Swisher; Robin L Bennett; Akiva P Novetsky; Gail P Jarvik; Olufunmilayo I Olopade; Paul J Goodfellow; Mary-Claire King; Jonathan F Tait; Tom Walsh
Journal:  J Mol Diagn       Date:  2012-05-30       Impact factor: 5.568

4.  Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors.

Authors:  Teresa Tapia; Susan V Smalley; Paulina Kohen; Alex Muñoz; Luisa M Solis; Alejandro Corvalan; Paola Faundez; Luigi Devoto; Mauricio Camus; Manuel Alvarez; Pilar Carvallo
Journal:  Epigenetics       Date:  2008-06-05       Impact factor: 4.528

5.  Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA.

Authors:  Kasmintan A Schrader; Donavan T Cheng; Vijai Joseph; Meera Prasad; Michael Walsh; Ahmet Zehir; Ai Ni; Tinu Thomas; Ryma Benayed; Asad Ashraf; Annie Lincoln; Maria Arcila; Zsofia Stadler; David Solit; David M Hyman; David Hyman; Liying Zhang; David Klimstra; Marc Ladanyi; Kenneth Offit; Michael Berger; Mark Robson
Journal:  JAMA Oncol       Date:  2016-01       Impact factor: 31.777

Review 6.  DNA repair, genome stability and cancer: a historical perspective.

Authors:  Penny A Jeggo; Laurence H Pearl; Antony M Carr
Journal:  Nat Rev Cancer       Date:  2015-12-15       Impact factor: 60.716

7.  A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease.

Authors:  Ali Amin Al Olama; Zsofia Kote-Jarai; Fredrick R Schumacher; Fredrik Wiklund; Sonja I Berndt; Sara Benlloch; Graham G Giles; Gianluca Severi; David E Neal; Freddie C Hamdy; Jenny L Donovan; David J Hunter; Brian E Henderson; Michael J Thun; Michael Gaziano; Edward L Giovannucci; Afshan Siddiq; Ruth C Travis; David G Cox; Federico Canzian; Elio Riboli; Timothy J Key; Gerald Andriole; Demetrius Albanes; Richard B Hayes; Johanna Schleutker; Anssi Auvinen; Teuvo L J Tammela; Maren Weischer; Janet L Stanford; Elaine A Ostrander; Cezary Cybulski; Jan Lubinski; Stephen N Thibodeau; Daniel J Schaid; Karina D Sorensen; Jyotsna Batra; Judith A Clements; Suzanne Chambers; Joanne Aitken; Robert A Gardiner; Christiane Maier; Walther Vogel; Thilo Dörk; Hermann Brenner; Tomonori Habuchi; Sue Ingles; Esther M John; Joanne L Dickinson; Lisa Cannon-Albright; Manuel R Teixeira; Radka Kaneva; Hong-Wei Zhang; Yong-Jie Lu; Jong Y Park; Kathleen A Cooney; Kenneth R Muir; Daniel A Leongamornlert; Edward Saunders; Malgorzata Tymrakiewicz; Nadiya Mahmud; Michelle Guy; Koveela Govindasami; Lynne T O'Brien; Rosemary A Wilkinson; Amanda L Hall; Emma J Sawyer; Tokhir Dadaev; Jonathan Morrison; David P Dearnaley; Alan Horwich; Robert A Huddart; Vincent S Khoo; Christopher C Parker; Nicholas Van As; Christopher J Woodhouse; Alan Thompson; Tim Dudderidge; Chris Ogden; Colin S Cooper; Artitaya Lophatonanon; Melissa C Southey; John L Hopper; Dallas English; Jarmo Virtamo; Loic Le Marchand; Daniele Campa; Rudolf Kaaks; Sara Lindstrom; W Ryan Diver; Susan Gapstur; Meredith Yeager; Angela Cox; Mariana C Stern; Roman Corral; Markus Aly; William Isaacs; Jan Adolfsson; Jianfeng Xu; S Lilly Zheng; Tiina Wahlfors; Kimmo Taari; Paula Kujala; Peter Klarskov; Børge G Nordestgaard; M Andreas Røder; Ruth Frikke-Schmidt; Stig E Bojesen; Liesel M FitzGerald; Suzanne Kolb; Erika M Kwon; Danielle M Karyadi; Torben Falck Orntoft; Michael Borre; Antje Rinckleb; Manuel Luedeke; Kathleen Herkommer; Andreas Meyer; Jürgen Serth; James R Marthick; Briony Patterson; Dominika Wokolorczyk; Amanda Spurdle; Felicity Lose; Shannon K McDonnell; Amit D Joshi; Ahva Shahabi; Pedro Pinto; Joana Santos; Ana Ray; Thomas A Sellers; Hui-Yi Lin; Robert A Stephenson; Craig Teerlink; Heiko Muller; Dietrich Rothenbacher; Norihiko Tsuchiya; Shintaro Narita; Guang-Wen Cao; Chavdar Slavov; Vanio Mitev; Stephen Chanock; Henrik Gronberg; Christopher A Haiman; Peter Kraft; Douglas F Easton; Rosalind A Eeles
Journal:  Hum Mol Genet       Date:  2012-10-12       Impact factor: 6.150

8.  Germline BRCA1 mutations increase prostate cancer risk.

Authors:  D Leongamornlert; N Mahmud; M Tymrakiewicz; E Saunders; T Dadaev; E Castro; C Goh; K Govindasami; M Guy; L O'Brien; E Sawyer; A Hall; R Wilkinson; D Easton; D Goldgar; R Eeles; Z Kote-Jarai
Journal:  Br J Cancer       Date:  2012-05-08       Impact factor: 7.640

9.  BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients.

Authors:  Z Kote-Jarai; D Leongamornlert; E Saunders; M Tymrakiewicz; E Castro; N Mahmud; M Guy; S Edwards; L O'Brien; E Sawyer; A Hall; R Wilkinson; T Dadaev; C Goh; D Easton; D Goldgar; R Eeles
Journal:  Br J Cancer       Date:  2011-09-27       Impact factor: 7.640

10.  Improving performance of multigene panels for genomic analysis of cancer predisposition.

Authors:  Brian H Shirts; Silvia Casadei; Angela L Jacobson; Ming K Lee; Suleyman Gulsuner; Robin L Bennett; Margaret Miller; Sarah A Hall; Heather Hampel; Fuki M Hisama; Lorraine V Naylor; Cathleen Goetsch; Kathleen Leppig; Jonathan F Tait; Sheena M Scroggins; Emily H Turner; Robert Livingston; Stephen J Salipante; Mary-Claire King; Tom Walsh; Colin C Pritchard
Journal:  Genet Med       Date:  2016-02-04       Impact factor: 8.822

View more
  437 in total

1.  Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients.

Authors:  Allison W Kurian; Kevin C Ward; Nadia Howlader; Dennis Deapen; Ann S Hamilton; Angela Mariotto; Daniel Miller; Lynne S Penberthy; Steven J Katz
Journal:  J Clin Oncol       Date:  2019-04-09       Impact factor: 44.544

Review 2.  [Familial prostate cancer and genetic predisposition].

Authors:  V H Meissner; M Jahnen; K Herkommer
Journal:  Urologe A       Date:  2021-03-15       Impact factor: 0.639

Review 3.  Cellular determinants and microenvironmental regulation of prostate cancer metastasis.

Authors:  Kiera Rycaj; Hangwen Li; Jianjun Zhou; Xin Chen; Dean G Tang
Journal:  Semin Cancer Biol       Date:  2017-04-11       Impact factor: 15.707

Review 4.  Clinical implications of mismatch repair deficiency in prostate cancer.

Authors:  Ramy Sedhom; Emmanuel S Antonarakis
Journal:  Future Oncol       Date:  2019-06-25       Impact factor: 3.404

5.  Two synchronous malignancies: nodular melanoma and renal cell carcinoma in a patient with an underlying germline BRCA2 mutation.

Authors:  Anson Snow; Charite Ricker; Gino K In
Journal:  BMJ Case Rep       Date:  2019-06-20

6.  Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family.

Authors:  Ciyu Yang; Angela G Arnold; Magan Trottier; Yukio Sonoda; Nadeem R Abu-Rustum; Oliver Zivanovic; Mark E Robson; Zsofia K Stadler; Michael F Walsh; David M Hyman; Kenneth Offit; Liying Zhang
Journal:  Breast Cancer Res Treat       Date:  2016-10-18       Impact factor: 4.872

7.  Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing.

Authors:  Srinivas R Viswanathan; Gavin Ha; Andreas M Hoff; Jeremiah A Wala; Jian Carrot-Zhang; Christopher W Whelan; Nicholas J Haradhvala; Samuel S Freeman; Sarah C Reed; Justin Rhoades; Paz Polak; Michelle Cipicchio; Stephanie A Wankowicz; Alicia Wong; Tushar Kamath; Zhenwei Zhang; Gregory J Gydush; Denisse Rotem; J Christopher Love; Gad Getz; Stacey Gabriel; Cheng-Zhong Zhang; Scott M Dehm; Peter S Nelson; Eliezer M Van Allen; Atish D Choudhury; Viktor A Adalsteinsson; Rameen Beroukhim; Mary-Ellen Taplin; Matthew Meyerson
Journal:  Cell       Date:  2018-06-18       Impact factor: 41.582

8.  Association Between CHEK2*1100delC and Breast Cancer: A Systematic Review and Meta-Analysis.

Authors:  Mingming Liang; Yun Zhang; Chenyu Sun; Feras Kamel Rizeq; Min Min; Tingting Shi; Yehuan Sun
Journal:  Mol Diagn Ther       Date:  2018-08       Impact factor: 4.074

9.  Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.

Authors:  Andrew J Aguirre; Jonathan A Nowak; Nicholas D Camarda; Richard A Moffitt; Arezou A Ghazani; Mehlika Hazar-Rethinam; Srivatsan Raghavan; Jaegil Kim; Lauren K Brais; Dorisanne Ragon; Marisa W Welch; Emma Reilly; Devin McCabe; Lori Marini; Kristin Anderka; Karla Helvie; Nelly Oliver; Ana Babic; Annacarolina Da Silva; Brandon Nadres; Emily E Van Seventer; Heather A Shahzade; Joseph P St Pierre; Kelly P Burke; Thomas Clancy; James M Cleary; Leona A Doyle; Kunal Jajoo; Nadine J McCleary; Jeffrey A Meyerhardt; Janet E Murphy; Kimmie Ng; Anuj K Patel; Kimberly Perez; Michael H Rosenthal; Douglas A Rubinson; Marvin Ryou; Geoffrey I Shapiro; Ewa Sicinska; Stuart G Silverman; Rebecca J Nagy; Richard B Lanman; Deborah Knoerzer; Dean J Welsch; Matthew B Yurgelun; Charles S Fuchs; Levi A Garraway; Gad Getz; Jason L Hornick; Bruce E Johnson; Matthew H Kulke; Robert J Mayer; Jeffrey W Miller; Paul B Shyn; David A Tuveson; Nikhil Wagle; Jen Jen Yeh; William C Hahn; Ryan B Corcoran; Scott L Carter; Brian M Wolpin
Journal:  Cancer Discov       Date:  2018-06-14       Impact factor: 39.397

10.  Pathogenic Variants in Cancer Predisposition Genes and Prostate Cancer Risk in Men of African Ancestry.

Authors:  Marco Matejcic; Yesha Patel; Jenna Lilyquist; Chunling Hu; Kun Y Lee; Rohan D Gnanaolivu; Steven N Hart; Eric C Polley; Siddhartha Yadav; Nicholas J Boddicker; Raed Samara; Lucy Xia; Xin Sheng; Alexander Lubmawa; Vicky Kiddu; Benon Masaba; Dan Namuguzi; George Mutema; Kuteesa Job; Dabanja M Henry; Sue A Ingles; Lynne Wilkens; Loic Le Marchand; Stephen Watya; Fergus J Couch; David V Conti; Christopher A Haiman
Journal:  JCO Precis Oncol       Date:  2020-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.